PTJ
UTHR icon

Paul Tudor Jones’s United Therapeutics UTHR Stock Holding History

Paul Tudor Jones’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,000
Closed -$14.2M – 4313
2026
Q1 		$14.2M Buy
24,000
+22,800
+1,900% +$11.4M 0.03% 566
2025
Q4 		$585K Buy
1,200
+600
+100% +$279K ﹤0.01% 2624
2025
Q3 		$252K Buy
+600
New +$202K ﹤0.01% 3088

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Paul Tudor Jones's UTHR Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in United Therapeutics (UTHR) in Q2 2026: 12,667 shares worth $6.86M. The stake represents 0.01% of the portfolio and ranks #1065 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in UTHR as recently as Q4 2025.

Paul Tudor Jones first reported a position in UTHR in Q2 2013 and has held it in 31 quarters since. The position peaked at $11.6M in Q3 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Paul Tudor Jones held 12,667 shares of United Therapeutics worth $6.86M as of Q2 2026.
  • United Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • United Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1065 holding.
  • Paul Tudor Jones first reported a position in United Therapeutics in Q2 2013 and has held it in 31 quarters since.
  • Paul Tudor Jones's United Therapeutics position peaked at $11.6M in Q3 2025.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.